Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 11/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23200947 | 0.88 | PREP (0.40) | PREPCXCR2PSMB5F2PRSS1 | |
| SCHEMBL23576452 | 0.82 | PREP (0.41) | PREPCXCR2PSMB5F2PSEN1 | |
| SCHEMBL2787596 | 0.81 | PREP (0.45) | PREPCXCR2PSMB5F2PSEN1 | |
| SCHEMBL20571080 | 0.79 | PREP (0.44) | PREPCXCR2PSMB5F2PRSS1 | |
| SCHEMBL21911461 | 0.79 | PREP (0.44) | PREPCXCR2PSMB5F2PRSS1 | |
| SCHEMBL23200663 | 0.78 | PREP (0.40) | PREPCXCR2PSMB5F2PRSS1 | |
| SCHEMBL23200672 | 0.74 | PSMB5 (0.39) | PREPCXCR2PSMB5F2PRSS1 | |
| SCHEMBL20571176 | 0.74 | PSMB5 (0.39) | PREPCXCR2PSMB5F2PRSS1 | |
| SCHEMBL23200757 | 0.74 | PREP (0.44) | PREPCXCR2PSMB5F2PRSS1 | |
| SCHEMBL23414423 | 0.74 | PREP (0.44) | PREPCXCR2PSMB5F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2021-07-01 | — | — | US | disclosed |
| EP-3802551-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | PREP 6/4885CXCR2 2165/4885PSMB5 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.